Novel approaches for vaccine development

Cell. 2021 Mar 18;184(6):1589-1603. doi: 10.1016/j.cell.2021.02.030.

Abstract

Vaccines are critical tools for maintaining global health. Traditional vaccine technologies have been used across a wide range of bacterial and viral pathogens, yet there are a number of examples where they have not been successful, such as for persistent infections, rapidly evolving pathogens with high sequence variability, complex viral antigens, and emerging pathogens. Novel technologies such as nucleic acid and viral vector vaccines offer the potential to revolutionize vaccine development as they are well-suited to address existing technology limitations. In this review, we discuss the current state of RNA vaccines, recombinant adenovirus vector-based vaccines, and advances from biomaterials and engineering that address these important public health challenges.

Publication types

  • Review

MeSH terms

  • Adenoviridae / genetics
  • Animals
  • Antigens, Viral / genetics
  • Biocompatible Materials
  • COVID-19 / prevention & control*
  • COVID-19 / virology
  • COVID-19 Vaccines / immunology*
  • COVID-19 Vaccines / therapeutic use*
  • Drug Delivery Systems / methods
  • Genetic Vectors / immunology
  • Humans
  • Immunogenicity, Vaccine
  • Liposomes
  • Nanoparticles
  • RNA, Messenger / chemical synthesis
  • RNA, Messenger / immunology
  • SARS-CoV-2 / immunology*
  • Vaccines, Synthetic / immunology*
  • Vaccines, Synthetic / therapeutic use*
  • mRNA Vaccines

Substances

  • Antigens, Viral
  • Biocompatible Materials
  • COVID-19 Vaccines
  • Lipid Nanoparticles
  • Liposomes
  • RNA, Messenger
  • Vaccines, Synthetic